G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET
Company Participants
Will Roberts - Investor Relations
Jack Bailey - Chief Executive Officer
Andrew Perry - Chief Commercial Officer
Raj Malik - Chief Medical Officer
John Umstead - Chief Financial Officer
Conference Call Participants
Gil Blum - Needham
Joseph Thome - TD Cowen
Laura Prendergast - Raymond James
David Nierengarten - Wedbush
Steve Bersey - H.C. Wainwright
Operator
Good day, and thank you for standing by. Welcome to the G1 Therapeutics First Quarter 2024 Financial Results. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Will Roberts. Please go ahead.
Will Roberts
Thank you, Victor. Good morning, everyone, and welcome to the G1 conference call to discuss our first quarter 2024 financial results and business update. The press release on these financial results was issued this morning and can be found in our News section of our corporate website, g1therapeutics.com.
On this morning's call, the team will provide a business overview of the 2024 first quarter, including an update on our commercial progress and clinical programs in that period with COSELA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. A Q&A session will follow the prepared remarks.
Before we begin, I want to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today, and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on such risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, May 1, 2024.
Joining me on the call today are Jack Bailey, our Chief Executive Officer; Andrew Perry, our Chief Commercial Officer; Dr. Raj Malik, our Chief Medical Officer; and John Umstead, our Chief Financial Officer.
I'll now turn the call over to Jack. Jack?